Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Triple-Drug strategy aims to boost remission in Hard-to-Treat leukemia

NCT ID NCT07712848

Recruiting now Disease control Sponsor: The Second Affiliated Hospital of Kunming Medical University Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether combining the targeted drug venetoclax with either a short course of decitabine or a modified DA regimen (daunorubicin and cytarabine) works better than the standard 3+7 DA regimen for adults newly diagnosed with acute myeloid leukemia. About 291 participants will be randomly assigned to one of three treatment groups. The study measures how many achieve complete remission after the first round of treatment, along with long-term survival and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
venetoclax combined with decitabine or daunorubicin and cytarabine
What this could lead to
If successful, this could identify a more effective and safer initial treatment for adults with acute myeloid leukemia, potentially improving remission rates and survival.
What could go wrong
This is an early-phase trial with a limited number of participants, so results may not apply to all patients. The treatments have significant side effects, including infection and bleeding risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML (ACUTE MYELOID LEUKEMIA)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Second Affiliated Hospital of Kunming Medical University

    RECRUITING

    Kunming, Yunnan, 650106, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.